

Client: Example Client ABC123

123 Test Drive

Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example** 

**DOB** 6/10/1946

Sex: Male

Patient Identifiers: 01234567890ABCD, 012345

**Visit Number (FIN):** 01234567890ABCD **Collection Date:** 01/01/2017 12:34

## HLA Class II Panel (DRB1, DQA1 and DQB1) by Next Generation Sequencing

HLA Class II-Locus DQA1*, Allele 2  O5: Perf  HLA Class II-Locus DQB1*, Allele 1  O2: Perf  HLA Class II-Locus DQB1*, Allele 2  O3: Perf	ormed By: 01 ormed By:
HLA Class II-Locus DQA1*, Allele 2  O5: Perf  HLA Class II-Locus DQB1*, Allele 1  O2: Perf  HLA Class II-Locus DQB1*, Allele 2  O3:	ormed By:  Ol ormed By:
HLA Class II-Locus DQA1*, Allele 2  O5: Perf  HLA Class II-Locus DQB1*, Allele 1  O2:	ormed By:
HLA Class II-Locus DQA1*, Allele 2 05:	
Peri	
HLA Class II-Locus DQA1*, Allele 1 03:	01 ormed By:
HLA Class II-Locus DRB1*, Allele 2 04:0	04 ormed By:
	01 RPXT ormed By:



## Performed By:

INTERPRETIVE INFORMATION: HLA Class II Panel
(DRB1, DQA1, DQB1)NGS
Purpose: To identify HLA-DRB1, DQA1 and DQB1 allelic
polymorphisms on specimens for transplant candidates and their
donors.
Methodology: PCR followed by next generation sequencing of
HLA-DRB1, DQA1 and DQB1 loci.
Analytical Sensitivity & Specificity: >99 percent.
Limitations: Rare diagnostic errors can occur due to primer site
mutations.
Test Results: Results are reported as HLA locus (DRB1, DQA1 or
DQB1)\* followed by the two-field (four digit) assigned allele.

Disclaimer Information:

HLA typing has been performed by one or more of the following methodologies: next generation sequencing (NGS) and/or sequence specific probe hybridization (SSOP). The NMDP code provides possible rare alleles that cannot be ruled out. Additional unknown DNA polymorphisms could exist outside of the regions analyzed, the significance of which is not known.

This test was developed and its performance characteristics determined by the Histocompatibility& Immunogenetics laboratory at the University of Utah Health. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Histocompatibility& Immunogenetics laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. Performed at:

## EER HLA Class II Panel, Interpretation

See Note

Access ARUP Enhanced Report using the link below:

-Direct access:

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
HLA Class II-Locus DRB1*, Allele 1	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:32:00 AM	
HLA Class II-Locus DRB1*, Allele 2	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:32:00 AM	
HLA Class II-Locus DQA1*, Allele 1	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:32:00 AM	
HLA Class II-Locus DQA1*, Allele 2	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:32:00 AM	
HLA Class II-Locus DQB1*, Allele 1	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:32:00 AM	
HLA Class II-Locus DQB1*, Allele 2	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:32:00 AM	
HLA Class II Panel, Interpretation	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:37:00 AM	
EER HLA Class II Panel, Interpretation	22-115-111865	4/25/2022 9:08:00 AM	4/26/2022 6:52:59 AM	5/2/2022 9:37:00 AM	

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical